VYVGART

This brand name is authorized in Austria, France, Croatia, Israel, Italy, Japan, Lithuania, Romania, United States

Active ingredients

The drug VYVGART contains one active pharmaceutical ingredient (API):

1 Efgartigimod alfa UNII 961YV2O515 - EFGARTIGIMOD ALFA

Efgartigimod alfa is a human IgG1 antibody fragment engineered for increased affinity to the neonatal Fc Receptor (FcRn). Efgartigimod alfa binds to FcRn, resulting in a reduction in the levels of circulating IgG including pathogenic IgG autoantibodies. Efgartigimod alfa does not affect the levels of other immunoglobulins (IgA, IgD, IgE or IgM), or those of albumin. Read about Efgartigimod alfa

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VYVGART Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AA58		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA58

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 66371262, 69419901
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9264
Country: IT	Agenzia del Farmaco	Identifier(s): 050235011, 050235023
Country: JP	医薬品医療機器総合機構	Identifier(s): 6399430A1029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095371
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69156001
Country: US	FDA, National Drug Code	Identifier(s): 73475-3041